Salute e Benessere
Matter Bio Successfully Closes $7M Seed Funding Round
Matter Bio tackles the problem of genome instability holistically, addressing the issue through a multi-pronged approach:
Matter Bio has assembled a world-class team of scientists and executives, including co-founders such as George Church , PhD, a pioneer in genome sequencing and gene editing, Jan Vijg, PhD, an expert in genome instability and somatic mutations, and Claudia Gravekamp, PhD, a world authority in attenuated bacterial therapeutics. The company operates at the forefront of longevity biotechnology, leveraging cutting-edge science and innovative approaches to address the complexities of aging.
"Genomic integrity is a cornerstone of longevity and healthspan extension," said George Church , Professor of Genetics at Harvard Medical School . "Matter Bio is pioneering a crucial approach in the fight against aging by focusing on the preservation of our genetic blueprint. I am excited to see the impact of their work on enhancing human health."
"Our investment in Matter Bio furthers our mission of supporting the cutting-edge interventions that promote longevity and combat aging," said Andrew Worden , Founding Partner of LifeSpan Vision Ventures. "Matter Bio's strong team, cutting-edge genomic preservation technologies, and early-stage partnerships give the company excellent prospects to succeed with its vision."
For more information about Matter Bio's history and mission, please visit matterbio.com.
Media Contact:
Media@matterbio.com
View original content:https://www.prnewswire.co.uk/news-releases/matter-bio-successfully-closes-7m-seed-funding-round-302157811.html